Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2017-2023
Historical Year
2024-2032
Forecast Year
Chemotherapy Induced Neutropenia Market Outlook
The chemotherapy induced neutropenia market size is expected to grow at a CAGR of 4.3% during the forecast period of 2024-2032, driven by the rising prevalence of cancer along with the growing demand for effective neutropenia management solutions across the 8 major markets.
Chemotherapy Induced Neutropenia Market Overview
Chemotherapy is the treatment modality that is used to treat different types of cancers. Chemotherapy induced neutropenia is a common risk associated with cancer treatment where neutrophils (a type of white blood cells) have abnormally low counts, making patients susceptible to infections. The market is experiencing a rise in the volume of cancer patients receiving chemotherapy, with over 1 million people in the United States undergoing the treatment annually. Consequently, it is projected to fuel the chemotherapy induced neutropenia demand in the forecast period.
The surge in the approval of treatment products by the health authorities is poised to support the market expansion. In November 2023 , Evive Biotech (a subsidiary of Yifan Pharmaceutical Co., Ltd.) and Acrotech Biopharma (a wholly owned subsidiary of Aurobindo Pharma USA, Inc.) announced the approval of Efbemalenograstim alfa, marketed under the brand name Ryzneuta, by the United States Food and Drug Administration (FDA) to treat chemotherapy induced neutropenia in adult patients with non-myeloid malignancies. The medication developed by Evive Biotech is the first innovative biologics proven to stimulate the production of neutrophils. Acrotech Biopharma will be responsible for the commercialization of the product in the United States. The penetration of such effective treatment options is anticipated to boost the chemotherapy induced neutropenia market growth.
The market is also driven by the increased acquisition and merger initiatives by the key market players to meet the clinical needs of the patients suffering from chemotherapy induced neutropenia. Moreover, the rising patient awareness and the advancement in the healthcare system will accelerate the market value in coming years.
Chemotherapy Induced Neutropenia Market Trends
| Key Trends | Description |
| Advancements in Granulocyte Colony-Stimulating Factor (G-CSF) Therapies | Recent advancements in G-CSF therapies include the development of longer-acting formulations and biosimilars, which offer patient convenience and potentially lower costs of treatment. |
| Increased Focus on Prophylactic Treatments | There is a growing focus on the prophylactic administration of neutropenia management drugs to prevent the onset of neutropenia and its complications, rather than treating it after it occurs. |
| Development of Personalized and Precision Medicine | The field of personalized medicine is influencing the market by offering tailored neutropenia management strategies based on individual patient risk factors, genetic predispositions, and specific chemotherapy regimens. |
| Integration of Predictive Analytics and Artificial Intelligence in Patient Monitoring | Technological advancements in predictive analytics and artificial intelligence (AI) are being explored for their potential to predict the risk and onset of neutropenia in chemotherapy patients. Such technologies could lead to earlier interventions and more precise management of neutropenia. |
Chemotherapy Induced Neutropenia Market Segmentation
Market Breakup by Drug Type
- Colony-Stimulating Factors (CSFs)
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Based on drug types, the market is segmented into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). These drugs stimulate the production of white blood cells to prevent or treat neutropenia.
Market Breakup by Application
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Ovarian Cancer
- Others
The chemotherapy induced neutropenia market report includes segmentation based on application as well. It includes breast cancer, lung cancer, colorectal cancer, ovarian cancer, and others. This market segment represents different types of cancers for which chemotherapy induced neutropenia treatments are utilized to manage or prevent complications.
Market Breakup by Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Others
Distribution channels in the market are online pharmacies, retail pharmacies, hospital pharmacies, and others. The robust network of these channels caters to the diverse needs of the patients and contributes to the chemotherapy induced neutropenia market share.
Market Breakup by End User
- Cancer Research Institutes
- Hospitals
- Clinics
- Others
End users of the market are cancer research institutes, hospitals, clinics, and other healthcare facilities.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America dominates the market share which can be attributed to the high prevalence and incidence rates of cancer in the region. Furthermore, the presence of a well-established healthcare system also supports market growth in the market.
Chemotherapy Induced Neutropenia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Lupin Limited
- Ligand Pharmaceuticals
- Biogenomics Limited
- Baxter International
- Apotex
- Evive Biotech
- BeyondSpring Pharmaceuticals
- Myelo therapeutics
- Cellerant Therapeutics
- Aileron Therapeutics
- Enzychem Lifesciences Corporation
- Spectrum Pharmaceuticals
- G1 Therapeutics
- Teva B.V
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Chemotherapy Induced Neutropenia Market Report
- How has the chemotherapy induced neutropenia market performed so far and how will it perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of cancer affect the market landscape?
- How does the rising volume of chemotherapy treatments impact the chemotherapy induced neutropenia market value?
- Which drug type of chemotherapy induced neutropenia will dominate the market share?
- Which application is expected to have a high market value in the coming years?
- Which end user will contribute significantly to the market segment?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032, driven by the rising prevalence of cancer along with the growing demand for effective neutropenia management solutions across the 8 major markets.
The market demand is driven by rising patient awareness and investments to bring advancements in the healthcare system.
One of the significant trends in the market is the surge in the approval of treatment products by the health authorities. In November 2023 , Evive and Acrotech Biopharma announced the approval of Ryzneuta by the United States Food and Drug Administration (FDA) to treat chemotherapy induced neutropenia in adult patients with non-myeloid malignancies.
Based on the drug type, the market is segmented into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Major end users of the market are cancer research institutes, hospitals, clinics, and other healthcare facilities.
Distribution channels in the market include online pharmacies, retail pharmacies, hospital pharmacies, and others.
The market is segmented by application into breast cancer, lung cancer, colorectal cancer, ovarian cancer, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China.
Key players involved in the market are Novartis AG, Lupin Limited, Ligand Pharmaceuticals, Biogenomics Limited, Baxter International, Apotex, Evive Biotech, BeyondSpring Pharmaceuticals, Myelo Therapeutics, Cellerant Therapeutics, Aileron Therapeutics, Enzychem Lifesciences Corporation, Spectrum Pharmaceuticals, G1 Therapeutics, and Teva B.V.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124